Bone Biologics Corporation
BBLG
$0.6899
$0.02393.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 450.40K | 521.30K | 459.20K | 657.90K | 712.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.55M | 951.00K | 809.70K | 903.50K | 1.16M |
| Operating Income | -1.55M | -951.00K | -809.70K | -903.50K | -1.16M |
| Income Before Tax | -1.52M | -941.00K | -783.70K | -866.00K | -1.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.52M | -941.00K | -783.70K | -866.00K | -1.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.52M | -941.00K | -783.70K | -866.00K | -1.55M |
| EBIT | -1.55M | -951.00K | -809.70K | -903.50K | -1.16M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.61 | -2.37 | -0.67 | -1.31 | -3.38 |
| Normalized Basic EPS | -0.38 | -0.34 | -0.42 | -0.82 | -1.55 |
| EPS Diluted | -0.61 | -2.37 | -0.67 | -1.31 | -3.38 |
| Normalized Diluted EPS | -0.38 | -0.34 | -0.42 | -0.82 | -1.55 |
| Average Basic Shares Outstanding | 2.48M | 1.75M | 1.17M | 660.90K | 459.00K |
| Average Diluted Shares Outstanding | 2.48M | 1.75M | 1.17M | 660.90K | 459.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |